Title: Psychiatric symptoms and syndromes transcending diagnostic boundaries in the multiplex families

Running title: Transdiagnostic manifestations in multiplex families

Authors: Vanteemar S Sreeraj, Bharath Holla, Dhruva Ithal, Ravi Kumar Nadella, Jayant Mahadevan, Srinivas Balachander, Furkhan Ali, Sweta Sheth, Janardhanan C. Narayanaswamy, Ganesan Venkatasubramanian, John P. John, Mathew Varghese, Vivek Benegal, Sanjeev Jain, YC Janardhan Reddy, ADBS Consortium[#], Biju Viswanath*.

Affiliations: Department of Psychiatry, National Institute of Mental health and Neurosciences (NIMHANS), Bengaluru, India

*Corresponding Author:

Dr. Biju Viswanath,
Associate Professor of Psychiatry,
National Institute of Mental Health and Neurosciences, Bangalore, India 560029
Phone: +91 80 2699 5791; Mob: +919480829594
Email: bijuv1@gmail.com

[#]Accelerator Program for Discovery in Brain disorders using Stem cells (ADBS) Consortium:, Naren P. Rao[1], Palanimuthu T. Sivakumar[1], Arun Kandasamy[1], Muralidharan Kesavan[1], Urvakhsh Meherwan Mehta[1], Odity Mukherjee[2], Meera Purushottam[1], Bhupesh Mehta[1], Thennarasu Kandavel[1], B. Binukumar[1], Jitender Saini[1], Deepak Jayarajan[1], A. Shyamsundar[1], Sydney Moirangthem[1], K. G. Vijay Kumar[1], Jagadisha Thirthalli[1], Bangalore N. Gangadhar[1], Pratima Murthy[1], Mitradas M. Panicker[3], Upinder S. Bhalla[3], Sumantra Chattarji[2,3], Padinjat Raghu[3] & Mahendra Rao[2]

1. National Institute of Mental Health and Neuro Sciences (NIMHANS)
2. Institute for Stem Cell Biology and Regenerative Medicine (InStem)
3. National Center for Biological Sciences (NCBS).

Abstract:

The Accelerator program for discovery in brain disorders using stem cells (ADBS) is an ongoing longitudinal study investigating the neurobiological aspects of five psychiatric disorders. This article explores the frequency of manifestations of different psychiatric symptoms and syndromes in the participants and their relatives from this multiplex family-based study. Families with two or more first-degree relatives (FDRs) with either Alzheimer's dementia, bipolar disorder, obsessive-compulsive disorder, substance use disorder or schizophrenia were identified, and all those who consented to participate from these families were evaluated. We screened 3,583 families between August 2016 and October 2019 and enrolled 481 families (1406 participants; 773 affected with any of the 5 disorders, and relatives) in ADBS. The participants had a very high familial prevalence with nearly a third of FDRs affected. Though similar disorders aggregated within the families, the majority (61%) of the families had members with dissimilar diagnoses. Approximately 15% of affected participants had been diagnosed to have two or more co-occurring syndromes over their lifetime. Diverse cross-cutting symptoms, not restricted to the index syndrome, were observed in participants across diagnostic categories. The pattern and extent of co-occurrence validate the need for a transdiagnostic approach accounting for the presence of various psychiatric manifestations in the individuals and their families. The espoused cohort will be useful for genetics, molecular and neurobiological evaluation of neuropsychiatric conditions.

Keywords: Familial aggregation, Prevalence rates, Alzheimer's dementia, Bipolar disorder, Obsessive-compulsive disorder, Substance use disorder, Schizophrenia**.**

1. Introduction

Psychiatric disorders are a significant cause of morbidity and ill health. A better understanding of the basic mechanisms of pathobiology that contribute to these syndromes is essential for improved interventions (1). Recent findings, using diverse strategies ranging from epidemiology, and descriptive psychopathology, to pathophysiology and genetics, suggest that the diagnostic categories (of the various syndromes) may not be distinct and that transdiagnostic studies are thus necessary for brain-based disorders (2-16). The pathogenesis, too, seems to be shared across different disorders (17). The transition in research from traditional categorical approaches to brain-based dimensional approaches has been proposed by the Research Domain Criteria (RDoC) project following suggestions by the National Institute of Mental Health (18, 19). This approach is further validated by emerging evidence from large-scale, cross-disorder genetic studies, that show a significant genetic overlap between multiple psychiatric disorders (3, 20-23). Such overlaps have also been found in terms of brain markers in recent transdiagnostic studies (8, 24). The presence of overlaps does not necessarily mean an absence of specific factors, though attempts to identify these have had equivocal success (17).

One of the reasons for difficulty in finding disorder-specific factors is that the single-disorder, as well as cross-disorder, studies have generally not paid adequate attention to the familial risk of other disorders. The risk of psychiatric conditions is known to be transmitted in families, perhaps through a combination of both genetic and environmental factors. Hence, familial risks of different disorders for a given individual should be considered while evaluating the disorder-specific factors. Individuals from families with multiple affected members could have a dense accumulation of the biological and environmental factors (25) that contribute to risk. The amount of overlap of symptoms and syndromes in the members of the multiplex families thus needs to be better documented and investigated. Hence, we aimed at evaluating the frequency of occurrence of different symptoms and syndromes in relatives of those with severe mental illness. The major psychiatric disorders do not necessarily 'breed true', and it is often observed that index probands have a family history of different psychiatric illnesses (26-30). The current analysis thus also aimed at evaluating the aggregation patterns of different disorders in multiplex families.

2. Methods

This study draws on data from the ADBS project, an ongoing longitudinal collaborative by the National Institute of Mental Health and Neurosciences (NIMHANS), the National Centre for Biological Sciences (NCBS) and the Institute for Stem Cell Science and Regenerative Medicine (InStem), which began in August 2016 (29). Individuals with a diagnosis of substance use disorder (SUD), bipolar disorder (BD), Alzheimer's dementia (AD), obsessive-compulsive disorder (OCD) or schizophrenia (SCZ) under clinical care at the hospital were screened for an additional presence of a first-degree relatives (FDR) with either the same or any of the other four disorders. A total of 3,583 patients (from August 2016 to October 2019) attending the adult psychiatry services and different specialty psychiatry clinics (Geriatric clinic/center for addiction medicine /Schizophrenia clinic/Obsessive-compulsive disorder clinic) of the NIMHANS were

screened. The study population was selected from a combination of modal instance sampling (multiplex family), diversity sampling (Representation of 5 different disorders) and convenience sampling (from a tertiary health care center) methods. Identified families with multiple affected individuals were invited to participate with as many members (affected as well as unaffected) from each family as possible. Written informed consent was obtained from each participant for participation in the study and using the generated data for future studies in anonymized form as approved by the NIMHANS institution ethics committee. A detailed pedigree was drawn and the family interview for genetic studies (FIGS) based screening for psychiatric disorders was carried out. This was performed by an independent interview of at least two informants by a trained mental health professional (psychiatrist/psychiatric social worker/clinical psychologist). All psychiatric diagnoses were corroborated by two trained psychiatrists with ascertainment using the Mini International Neuropsychiatric Interview (MINI)(31) and in accordance with DSM-IV-TR (32). Requisite data for the current study was used after approval from the resource allocation committee of the ADBS.

2.1. Baseline characteristics of the participants

The biographic and clinical profile of the initial 1406 participants from 481 multiplex families is described in this paper. Diagnoses within the main DSM-IV category of SCZ and related disorders were subsumed under SCZ and both bipolar I & II disorders were considered as BD. Individuals who had met criteria more than one of the psychiatric diagnoses were grouped as "Complex severe mental illness (Complex SMI)". Schizoaffective disorder, bipolar type, was considered as Complex SMI and analyzed as individuals having phenotypes of both SCZ and BD. Dependence on any of the psychotropic substances in their lifetime, excluding nicotine, were considered as SUD. Some of the relatives who were found to have psychiatric disorders other than the five disorders under study were grouped as "other psychiatric disorders" and those without any axis-I psychiatric condition were regarded as "unaffected relatives".

DSM 5 self-rated Level-1 cross-cutting symptom measure-adult (33) was used to elicit dimensional psychiatric symptom profile of the participants (n=1373; missing=33 which included 25 participants aged less than 18 years) in the past 2 weeks. It measures the frequency of the symptoms in the past two weeks and those symptoms crossing the threshold were counted as significant symptoms. The proportion of individuals with each significant symptom prompting clinical attention was calculated across each diagnostic category.

2.2. Clinical profile of the families

The identified families could be further defined as "families with similar disorders" (all affected individuals have the same syndrome) or "families with dissimilar disorders" (members may have any of the five disorders in the family) based on the FIGS assessment of FDR and second-degree relatives (SDR) of

each participant in the study. The prevalence of psychiatric morbidities in FDRs and SDRs of the study participants from multiplex families was calculated with FIGS based on family history data.

As multiple members from a single-family are included as probands, the same relatives would be included independently multiple times in the series. For example., if two siblings participated in the study, their parents would be considered twice for the prevalence estimation. To overcome the unequal probabilities in the sample design, a complex sampling design statistic in IBM® SPSS® Statistic version 23.0 (IBM® corp,) was used for the analysis of prevalence rates. Each family was considered a cluster and the estimates were weighted for the number of participants from each family. A simple random sample design was assumed within the clusters for the standard error calculation with finite population correction (34, 35).

Lifetime prevalence in relatives was calculated as the proportion of relatives who have ever had a psychiatric disorder at any time in their life up to the time of assessment. Similar to Weinberg's shorter method, relatives who were below the age at risk for developing psychiatric conditions (<13 years) were excluded from this calculation (36). As individuals of all the age groups are potentially at risk for developing AD in their lifetime, we did not use the age correction for at-risk age and above-risk age. Due to the unavailability of data, niece/nephew and grandchildren were not considered in the SDRs.

The prevalence of each of the five disorders in the relatives was calculated separately (37). Also, the transdiagnostic prevalence was calculated for the presence of any of the five diagnoses within the family. They were described across participant's diagnoses. Thereafter, the prevalence rates (P) and prevalence ratio (PR) of having similar and dissimilar diagnoses were calculated for each of the five diagnoses. An example formula for BD is shown below:

$P_{Similar\ diagnosis\ for\ BD}$ = [total number of BD FDRs of BD participants/ total number of FDRs of BD participants above 13 years of age] x 100.

$P_{Dissimilar\ diagnosis\ for\ BD}$ = [total number of FDRs with AD or OCD or SCZ or SUD of BD participants/ total number of FDRs of BD patients above 13 years of age] x 100.

$P_{Similar\ diagnosis\ for\ BD\ among\ affected}$ = $P_{Similar\ diagnosis\ for\ BD}$ / ($P_{Similar\ diagnosis\ for\ BD}$ + $P_{Dissimilar\ diagnosis\ for\ BD}$)

P_{Ratio} = $P_{Similar\ diagnosis\ for\ BD}$ / $P_{Dissimilar\ diagnosis\ for\ BD}$

Similarly, P and PR were calculated for the psychiatric conditions from the extended relatives (consisting of both FDR+SDR).

3. Results

3.1. Psychiatric symptoms and syndromes in the participants

Among 1406 individuals, 773 (55%) had one of the five psychiatric diagnoses under the study (table 1). From among this set, 114 (15%) had two or more of the five syndromes in their lifetime. The remaining 633 (45%) individuals who participated from these families did not have any of these five diagnoses.

From among this set, 82 (13%) individuals with any other diagnosable psychiatric condition were grouped as "other psychiatric disorders" (table 1) and the individuals who did not have any diagnosable psychiatric condition were termed "unaffected relatives". From among all persons with a DSM-IV diagnosis (773+82=855), 206 (24%) had lifetime co-occurrence of two DSM-IV syndromes.

Aged between 12-95 years, 57% of the sample were males. The male preponderance was observed in SUD, complex SMI and OCD, whereas females were frequent in the other psychiatric disorder groups. Only 70% of the participants were staying married with 40-50% of SCZ, complex SMI, OCD and BD participants remaining single (unmarried/ separated). Nearly 20% of the affected participants were unemployed. Unemployment rates were more than 30% in SCZ, complex SMI and AD groups. Individuals with OCD had the youngest age of onset (AAO) and were younger than the other groups, while those with Alzheimer's disease were the oldest. The average illness duration (overall: 14 ±12 years) was more than a decade in all diagnostic groups except AD. (supplementary table S1).

DSM-5 cross-cutting symptom measure revealed that only a third (34%) of the sample had no psychiatric symptom above the clinical frequency threshold. While 20% had one symptom, four participants had ten out of thirteen clinically significant domain symptoms (for the entire range across each group see figure S1). Forty percent of the unaffected relatives (without any diagnosable psychiatric syndrome) had at least one significant psychiatric symptom. Overall, in the study participants, depressive symptoms (26%) were the most common reported symptom followed by somatic symptoms (24%), substance use (23%), anxiety (20%) and sleep (20%). Suicidal ideation was present in 11% of the individuals in the last two weeks. Dissociative symptoms (3%), mania (6%) and psychotic symptoms (8%) were found to have the least point prevalence in this sample. Other symptoms like memory problems, anger problems, obsessive-compulsive symptoms, and personality dysfunction were detected in more than one-tenth of the individuals (Figure 2). Patients with SUD, OCD, and AD had respective symptom domains (87%, 91% & 87%, respectively) as the most prevalent. Depression was the most prevalent clinical symptom in the prior two-weeks in patients with BD (22%), SCZ (33%), complex SMI (43%) and other psychiatric disorders (41%) groups.

3.2. The pattern of aggregation of psychiatric diagnosis within the families
The 481 multiplex families in the study have a median of 3 (range: 1-14, mean-2.9, SD-1.3) individuals participating from each family. Families with differing syndromes in affected individuals were more frequent (61%, 295 families). In the other 186 families, all affected individuals had the same diagnosis. SUD families were the majority with 49% (92 families) of all families with similar disorders, and each of the remaining four diagnoses had only 10%-15% share (figure 1a). The majority of participants with SUD (68%) were from families with similar diagnoses, but this proportion was lower in other diagnoses (AD-38%, OCD-39%, SCZ-27%, BD-25%) (figure 1b).

The lifetime prevalence of psychiatric syndromes was calculated among relatives (SDRs=19,559, 14.18±5.45 per participant, FDRs=9,241, 6.7±3.18 per participant) of 1379 participants from 477 families. Though one another affected FDR was the minimum inclusion criteria, an average of 2.12 (±1.35) FDRs and an additional 1.05 (±1.66) SDR of the affected participants were found to have one of the five conditions. Twenty-seven individuals were excluded due to insufficient FIGS data. The overlapping relatives within the families are adjusted for double-counting using complex sample statistics, as described in the methods section. On estimating the prevalence, 33% (95% CI: 31%-35%) of FDRs and 23% (21%-24%) of extended relatives of the participants had any of the five diagnoses. This implies that every one in three FDR and one in the fifth SDR of a person from multiplex families was affected with any of the five disorders. This is much higher than the general population prevalence of these disorders in India. A similar trend was observed in FDRs for all five disorders [SUD: 10% (CI:8%-11%), BD: 8% (6%-11%), SCZ: 8% (6%-9%), OCD: 5% (3%-6%) and AD: 2% (2%-3%)]. The same order of frequency was noted even after adding SDRs though it was lesser than the prevalence in FDRs alone (Figure 3 & Table 2).

The prevalence of affected FDRs was least for participants with AD at 20% (16%-23%) and highest for BD at 37% (28%-45%) (supplementary table S2). Affected participants had a higher prevalence of the same disorder in their relatives (11%-26% in FDRs, 9%-23% in extended relatives) than the other four disorders put together (6%-12% in FDRs, 4%-9% in SDRs). This suggests that similar diagnoses do aggregate in the multiplex families. However, the occurrence of other disorders was also quite significant. Nearly every third affected FDR of the participants with AD, SCZ, OCD, and BD had a different diagnosis (Table 3).

4. Discussion

Kessler et al. (38) observed that "*Although mental disorders are widespread, serious cases are concentrated among a relatively small proportion of cases with high comorbidity*". The "serious cases" in this study were selected from a large tertiary psychiatric hospital after screening for the presence of strong family history to achieve the project objectives (29). The five disorders (SUD, BD, SCZ, OCD, and AD) opted in the project cause significant disability and impose a burden on the individuals, their families and the society. An average illness duration of 14 years in the affected participants with nearly 20% unemployment rates (against the national average of 7.92% (9), and the high numbers remaining single/separated highlights the social decline as a consequence of psychiatric disorders in these families.

The identified participants had a high familial risk, with nearly 1/3rd of FDRs affected. The majority of multiplex families had members with dissimilar diagnoses and not just the same diagnosis. A good proportion of affected participants had also been diagnosed to have co-occurring syndromes over their lifetime. Diverse cross-cutting symptoms, not restricted to the index syndrome, are also observed in

participants, both with the diagnoses of interest, as well as in a significant proportion of apparently unaffected FDRs.

4.1. Phenotypic diversity: symptom overlap across diagnostic groups

A vast amount of phenotypic diversity is observed within and across individuals. As much as 15% of the individuals with these five psychiatric disorders had co-occurrence of two or more of these syndromes, during their course of illness. If we include any DSM-IV diagnosis, the number goes up to 24%. Even in those without a comorbid diagnosis, the subsyndromal psychiatric symptoms were found across nosological categories(15). Overall one in every four participants had frequent depressive symptoms crossing the threshold. Reporting of the suicidal ideation in more than 10% of them in the preceding two weeks echoes the severity of psychological problems in such families. Although most of the patients with varied diagnoses were on treatment and in different stages of recovery, the cross-sectional evaluation of psychiatric symptoms in the prior two weeks suggests the presence of a gamut of behavioral and psychological phenotypes. Symptoms transcending across traditional diagnostic boundaries highlight the need for a symptom-based approach (39-43) and a dimensional approach suggested by the RDoC project (19, 44).

4.2. Clinical status of "unaffected" FDRs

A significant proportion (12.4%) of FDRs who were included in the study for their at-risk status were found to have a diagnosable psychiatric diagnosis on structured clinical evaluation. Among the remaining relatives without any psychiatric morbidity, 39% had a psychiatric symptom crossing the threshold of clinical significance in the DSM-V cross-cutting symptoms measure. A higher proportion of symptoms and psychiatric syndromes in the apparently unaffected FDRs could indicate their higher biological vulnerability(30). The psychosocial burden posed by the multiple relatives with SMI could also have led to the development of psychological symptoms in the unaffected family members (45-47). This further necessitates long-term follow up of such individuals to understand the biological and psychosocial interactions associated with the evolution of severe phenotypes, as envisaged in ADBS.

4.3. Familial aggregation pattern of psychiatric diagnoses

The ascertainment of higher familial risk in this sample is intended to identify 'genetically enriched' pedigrees. High familial risk in this sample was demonstrated by the presence of psychiatric disorders in nearly one-third of FDRs and nearly 22% of extended relatives of the participants. A recent national mental health survey (NMHS) in India indicates a lifetime prevalence of SUD (4.6%), BD (0.5%), OCD (0.8%), and SCZ (1.4%) in adult general population (9). Maximum reported Indian prevalence of AD is 3.77% in those aged >55 years which equates to around 0.8% of the Indian adult population (48). Thus, the combined prevalence rates of these disorders in the relatives of the participants were 3-4 times greater than that in the general population.

Increased familial risk is the major contributor to the propensity to develop severe mental illnesses (49, 50). The majority of the families of the participants had different diagnoses among their members than a single specific syndrome (295 vs 196 families). This was despite the fact that families with similar or dissimilar diagnoses were not explicitly chosen. Such diverse diagnoses within families are reported earlier (15, 28, 51-54). Thus, these transdiagnostic multiplex families may represent a real-world scenario much better than the syndrome specific multiplex families. However, similar diagnoses did tend to aggregate within the relatives. The prevalence of similar diagnoses was 1.5 to 4 times that of a dissimilar diagnosis, the highest aggregation of similar diagnoses being seen in SUD. This higher familial prevalence of similar diagnosis acknowledges, though indistinct, the boundaries in existing diagnostic categorization. There is hence a need to design etiological studies within this transdiagnostic framework (4, 54-57).

3.4 Implications:

Transdiagnostic research is yielding novel insights into role of the neuronal markers (8, 10, 12, 20, 24, 58), molecular(7, 59, 60), genetic (3, 5, 7, 22, 28, 49, 50) as well as psychosocial factors (13, 61). Pleiotropic genetic loci associated with multiple psychiatric conditions are being identified (62). Shared genetic and environmental factors within and across families might explain greater variance (26, 49) of outcomes. An understanding of mechanisms that are unique as well as shared across disorders considering interindividual and intrafamilial phenotypic diversity is thus necessary(18, 19, 44). The bio-repository comprised of this "enriched" sample will be maximally representative of individuals with severe psychiatric disorders and those with very high susceptibility; and, thus, provide a greater opportunity in answering several questions related to the neurobiology and pathogenesis of psychiatric disorders. ADBS intends to make the data and resources generated from its research activities publicly available in a timely manner and encourages sharing data and resources with external investigators before the designated embargo periods. External investigators can embark on a formal collaboration with ADBS investigators to use the data and resources with approval from the data sharing and management board and/or resource sharing and management board of ADBS.

4.4. Limitations

Few limitations are to be acknowledged. The transdiagnostic approach is limited to the affected status of five specific psychiatric disorders. This a major step in using a transdiagnostic approach in understanding the biological bases of severe mental disorders; but is inadequate to interrogate mechanisms of common syndromes of anxiety and depressive disorders (14). The five syndromes become manifest from young adult life to late life (AD). A uniform age-at-risk of 13 years and above may not be equally representative of each of the syndromes. A non-probabilistic sampling method was applied for the efficient identification of highly vulnerable families. Hence, we need to acknowledge the possibility of selection bias and

limitations in generalizing the estimates to the wider universe of multiplex families. The affected status of non-participating family members is ascertained by family history methods, and thus the knowledge of mildly affected members or those who chose not to disclose their family history may have been missed. However, family history was obtained from at least two FDRs that would partially compensate for any possible reporting bias. An unbiased ascertainment for non-occurrence is not possible in relatives given the persistent risk for future occurrence. Nevertheless, the obtained estimates are conservative and the actual familial risk might be much higher than reported.

4.5. Conclusions

The ADBS study is congregating participants from extremely dense families with five psychiatric disorders. Most of these families have their members unrestricted to a single-diagnosis with a high prevalence of co-occurrence of syndromes in the affected individuals. In addition, a significant proportion of participants, across all diagnostic groups (including the unaffected relatives) have subsyndromal psychiatric symptoms of diverse domains. However, similar syndromes aggregate within the families and specific symptoms aggregate within individuals with particular disorders. This sample would thus be helpful in elucidating the pathogenetic mechanisms that are specific and shared across disorders.

References

1.   Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry. 2016;3(2):171-8.

2.   International Obsessive Compulsive Disorder Foundation Genetics C, Studies OCDCGA. Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. Mol Psychiatry. 2018;23(5):1181-8.

3.   Maier R, Moser G, Chen GB, Ripke S, Cross-Disorder Working Group of the Psychiatric Genomics C, Coryell W, et al. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. Am J Hum Genet. 2015;96(2):283-94.

4.   Mitropoulos GB. The DSM-ICD diagnostic approach as an essential bridge between the patient and the "big data". Psychiatriki. 2018;29(3):249-56.

5.   Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics C, Han B, Wu Y, Mignot E, Ollila HM, et al. Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. Hum Mol Genet. 2019.

6.   Docherty AR, Moscati AA, Fanous AH. Cross-Disorder Psychiatric Genomics. Curr Behav Neurosci Rep. 2016;3(3):256-63.

7.   Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9(1):233.

8.   Wang S, Gong G, Zhong S, Duan J, Yin Z, Chang M, et al. Neurobiological commonalities and distinctions among 3 major psychiatric disorders: a graph theoretical analysis of the structural connectome. J Psychiatry Neurosci. 2019;44(5):1-8.

9.   Gururaj G, Varghese M, Benegal V, N R, K P, Singh L, et al. National Mental Health Survey of India, 2015-16: Prevalence, patterns and outcomes. Bengaluru: National Institute of Mental Health and Neuro Sciences, NIMHANS Publication; 2016.

10.   Janiri D, Moser DA, Doucet GE, Luber MJ, Rasgon A, Lee WH, et al. Shared Neural Phenotypes for Mood and Anxiety Disorders: A Meta-analysis of 226 Task-Related Functional Imaging Studies. JAMA Psychiatry. 2019:1-8.

11.   Mitelman SA. Transdiagnostic neuroimaging in psychiatry: A review. Psychiatry Res. 2019;277:23-38.

12.   Romanowska S, MacQueen G, Goldstein BI, Wang J, Kennedy SH, Bray S, et al. Neurocognitive deficits in a transdiagnostic clinical staging model. Psychiatry Res. 2018;270:1137-42.

13.   Albott CS, Forbes MK, Anker JJ. Association of Childhood Adversity With Differential Susceptibility of Transdiagnostic Psychopathology to Environmental Stress in Adulthood. JAMA Netw Open. 2018;1(7):e185354.

14.   Fusar-Poli P, Solmi M, Brondino N, Davies C, Chae C, Politi P, et al. Transdiagnostic psychiatry: a systematic review. World Psychiatry. 2019;18(2):192-207.

15.   First MB, Rebello TJ, Keeley JW, Bhargava R, Dai Y, Kulygina M, et al. Do mental health professionals use diagnostic classifications the way we think they do? A global survey. World Psychiatry. 2018;17(2):187-95.

16.   van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry. 2016;15(2):118-24.

17.   Caspi A, Moffitt TE. All for One and One for All: Mental Disorders in One Dimension. Am J Psychiatry. 2018;175(9):831-44.

18.   Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748-51.

19.   Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13(1):28-35.

20.   Schork AJ, Brown TT, Hagler DJ, Thompson WK, Chen CH, Dale AM, et al. Polygenic risk for psychiatric disorders correlates with executive function in typical development. Genes Brain Behav. 2019;18(4):e12480.

21.   Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395).

22.   Jia X, Yang Y, Chen Y, Cheng Z, Du Y, Xia Z, et al. Multivariate analysis of genome-wide data to identify potential pleiotropic genes for five major psychiatric disorders using MetaCCA. J Affect Disord. 2019;242:234-43.

23.   Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291-5.

24.   Gong Q, Scarpazza C, Dai J, He M, Xu X, Shi Y, et al. A transdiagnostic neuroanatomical signature of psychiatric illness. Neuropsychopharmacology. 2019;44(5):869-75.

25.   Okayama T, Hashiguchi Y, Kikuyama H, Yoneda H, Kanazawa T. Next-generation sequencing analysis of multiplex families with atypical psychosis. Transl Psychiatry. 2018;8(1):221.

26.   Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry. 2003;60(9):929-37.

27.   Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, et al. Multigenerational transmission of liability to psychiatric illness in offspring of parents with bipolar disorder. Bipolar Disord. 2018.

28.   Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234-9.

29.   Viswanath B, Rao NP, Narayanaswamy JC, Sivakumar PT, Kandasamy A, Kesavan M, et al. Discovery biology of neuropsychiatric syndromes (DBNS): a center for integrating clinical medicine and basic science. BMC Psychiatry. 2018;18(1):106.

30.   Chou IJ, Kuo CF, Huang YS, Grainge MJ, Valdes AM, See LC, et al. Familial Aggregation and Heritability of Schizophrenia and Co-aggregation of Psychiatric Illnesses in Affected Families. Schizophr Bull. 2017;43(5):1070-8.

31.   Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 4-57.

32.   AmericanPsychiatricAssociation. Diagnostic and statistical manual of mental disorders (4th ed., Text Revision). Washington, DC2000.

33.   Narrow WE, Clarke DE, Kuramoto SJ, Kraemer HC, Kupfer DJ, Greiner L, et al. DSM-5 field trials in the United States and Canada, Part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5. Am J Psychiatry. 2013;170(1):71-82.

34.   Hahs-Vaughn DL, McWayne CM, Bulotsky-Shearer RJ, Wen X, Faria AM. Methodological considerations in using complex survey data: an applied example with the Head Start Family and Child Experiences Survey. Eval Rev. 2011;35(3):269-303.

35.   Lin DY, Tao R, Kalsbeek WD, Zeng D, Gonzalez F, 2nd, Fernandez-Rhodes L, et al. Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos. Am J Hum Genet. 2014;95(6):675-88.

36.   Chase GA, Kramer M. The abridged census method as an estimator of lifetime risk. Psychol Med. 1986;16(4):865-71.

37.   Cardno AM, P. Quantitative gentics. McGuffin PO, M. J.; Gottesman, I. I., editor. Oxford, England: Oxford University Press; 2002.

38.   Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-27.

39.   Schmidt U. A plea for symptom-based research in psychiatry. Eur J Psychotraumatol. 2015;6:27660.

40.   Krueger RF, Kotov R, Watson D, Forbes MK, Eaton NR, Ruggero CJ, et al. Progress in achieving quantitative classification of psychopathology. World Psychiatry. 2018;17(3):282-93.

41.   Parnas J. Differential diagnosis and current polythetic classification. World Psychiatry. 2015;14(3):284-7.

42.   Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. J Abnorm Psychol. 2017;126(4):454-77.

43.   Reininghaus U, Bohnke JR, Chavez-Baldini U, Gibbons R, Ivleva E, Clementz BA, et al. Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). World Psychiatry. 2019;18(1):67-76.

44.   Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.

45.   Koschorke M, Padmavati R, Kumar S, Cohen A, Weiss HA, Chatterjee S, et al. Experiences of stigma and discrimination faced by family caregivers of people with schizophrenia in India. Soc Sci Med. 2017;178:66-77.

46.   Viana MC, Gruber MJ, Shahly V, Alhamzawi A, Alonso J, Andrade LH, et al. Family burden related to mental and physical disorders in the world: results from the WHO World Mental Health (WMH) surveys. Braz J Psychiatry. 2013;35(2):115-25.

47.   Murthy RS. Family interventions and empowerment as an approach to enhance mental health resources in developing countries. World Psychiatry. 2003;2(1):35-7.

48.   Mathuranath PS, Cherian PJ, Mathew R, Kumar S, George A, Alexander A, et al. Dementia in Kerala, South India: prevalence and influence of age, education and gender. Int J Geriatr Psychiatry. 2010;25(3):290-7.

49.   Sandstrom A, Sahiti Q, Pavlova B, Uher R. Offspring of parents with schizophrenia, bipolar disorder, and depression: a review of familial high-risk and molecular genetics studies. Psychiatr Genet. 2019;29(5):160-9.

50.   Pettersson E, Lichtenstein P, Larsson H, Song J, Attention Deficit/Hyperactivity Disorder Working Group of the iPsych-Broad-Pgc Consortium ASDWGoti-B-PGCCBDWG, Tourette

Syndrome Working Group of the Pgc SCSUDWGotPGC, et al. Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls. Psychol Med. 2019;49(7):1166-73.

51.   Viswanath B, Narayanaswamy JC, Cherian AV, Reddy YC, Math SB. Is familial obsessive-compulsive disorder different from sporadic obsessive-compulsive disorder? A comparison of clinical characteristics, comorbidity and treatment response. Psychopathology. 2011;44(2):83-9.

52.   Maier W. Genetic epidemiology of psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 1993;243(3-4):119-20.

53.   Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet. 2003;123C(1):48-58.

54.   Cheng CM, Chang WH, Chen MH, Tsai CF, Su TP, Li CT, et al. Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: a nationwide population-based study. Mol Psychiatry. 2018;23(8):1756-63.

55.   First MB. Preserving the clinician-researcher interface in the age of RDoC: the continuing need for DSM-5/ICD-11 characterization of study populations. World Psychiatry. 2014;13(1):53-4.

56.   Maj M. Why the clinical utility of diagnostic categories in psychiatry is intrinsically limited and how we can use new approaches to complement them. World Psychiatry. 2018;17(2):121-2.

57.   Kendler KS. Classification of psychopathology: conceptual and historical background. World Psychiatry. 2018;17(3):241-2.

58.   de Lange SC, Scholtens LH, Alzheimer's Disease Neuroimaging I, van den Berg LH, Boks MP, Bozzali M, et al. Shared vulnerability for connectome alterations across psychiatric and neurological brain disorders. Nat Hum Behav. 2019;3(9):988-98.

59.   Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, et al. A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA Psychiatry. 2017;74(12):1206-13.

60.   Pinto JV, Moulin TC, Amaral OB. On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: A systematic review. Neurosci Biobehav Rev. 2017;83:97-108.

61.   Belhadj Kouider E, Petermann F. [Common Risk Factors of Depressive and Anxiety Symptomatics in Childhood and Adolescence: A Systematic Review from Transdiagnostic Perspectives]. Fortschr Neurol Psychiatr. 2015;83(6):321-33.

62.   Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address pmhe, Cross-Disorder Group of the Psychiatric Genomics C. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell. 2019;179(7):1469-82 e11.

Table 1: Diagnostic description of participants

	Number of individuals	Percentage
Total Participants*	**1406**	
Affected (with any of 5 disorder) Participants	**773**	**100.00%**
SUD	165	21.34%
BD	151	19.53%
Schizophrenia	150	19.41%
OCD	117	15.14%
AD	76	9.83%
Total Complex SMI	114	14.75%
Complex SMI		
OCD + Schizophrenia	27	23.68%
BD + SUD	22	19.3%
Schizophrenia + SUD	20	14.91%
SAD	17	14.91%
BD + OCD	12	10.53%
AD + SUD	6	5.26%
BD + OCD + SUD	2	1.75%
OCD + SAD	2	1.75%
OCD + SUD	2	1.75%
SAD + SUD	2	1.75%
AD + BD	1	0.88%
AD + Schizophrenia	1	0.88%
Participating relatives of affected individuals (without any of the 5 disorder)	**633**	**100.00%**
No Psychiatric disorder (includes Nicotine dependence)	**551**	**87.05%**
Other psychiatric disorders	**82**	**12.95%**

Other Psychiatric disorders		
RDD	16	19.51%
Depression	14	17.07%
Alcohol Abuse	10	12.2%
Dysthymia	10	12.2%
Generalized Anxiety Disorder	10	12.2%
Adjustment Disorder	6	7.32%
Agoraphobia	3	3.66%
Panic Disorder	3	3.66%
ADHD	2	2.44%
Generalized Anxiety Disorder + Alcohol Abuse + OCPD	1	1.22%
Depression + Alcohol Abuse	1	1.22%
Depression + Dysthymia	1	1.22%
Dissociation	1	1.22%
Dysthymia + Anxiety	1	1.22%
Mild Cognitive Impairment	1	1.22%
Primary Insomnia	1	1.22%
Social Phobia	1	1.22%

SUD- Substance use disorder; BD- Bipolar Disorder; OCD- Obsessive compulsive disorder; AD- Alzheimer's dementia; SMI- Severe mental illness; SAD- Schizoaffective disorder; ADHD- Attention Deficit Hyperactivity Disorder; RDD – Recurrent Depressive Disorder; Depression – Major Depressive Disorder, Single episode; OCPD – Obsessive Compulsive Personality Disorder.

Table 2: <u>Prevalence rates of similar and dissimilar psychiatric disorders and prevalence ratios across diagnostic categories</u>

	FDRs					FDR+SDRs				
	$P_{Similar\ diagnosis}$	$P_{Dissimilar\ diagnosis}$	$P_{Similar\ diagnosis\ among\ affected}$	$P_{Dissimilar\ diagnosis\ among\ affected}$	PR	$P_{Similar\ diagnosis}$	$P_{Dissimilar\ diagnosis}$	$P_{Similar\ diagnosis\ among\ affected}$	$P_{Dissimilar\ diagnosis\ among\ affected}$	PR
SUD	25.91%	6.42%	0.80	0.20	4.04	22.89%	3.85%	0.86	0.14	5.94
BD	24.72%	12.03%	0.67	0.33	2.05	13.01%	8.63%	0.60	0.40	1.51
Schizophrenia	20.13%	11.83%	0.63	0.37	1.70	9.35%	7.33%	0.56	0.44	1.28
OCD	20.73%	10.71%	0.66	0.34	1.94	10.24%	8.76%	0.54	0.46	1.17
AD	11.41%	8.24%	0.58	0.42	1.38	10.60%	7.31%	0.59	0.41	1.45

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.

Most of the families had dissimilar diagnoses. Half of all the families with one type of diagnosis consisted of only substance use disorder. Unlike participants from other diagnostic categories, higher number of participants with substance use disorder hailed from families with only one type of diagnosis.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; SCZ- Schizophrenia; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness; Others- Other psychiatric disorders.

Figure 2: Point Prevalence of psychiatric symptoms in participants across diagnostic categories as measured by DSM5 level-1 cross-cutting measure

various domains of psychiatric symptom crossing the threshold for clinical significance are observed in participants across all diagnostic categories. A significant proportion of the apparently unaffected participants also have different sub-syndromal clinical symptoms. This indicates the phenotypic diversity within the clinical categories.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; SCZ- Schizophrenia; AD- Alzheimer's Dementia; cSMI- Complex Severe Mental Illness, Other PsyD- Other Psychiatric Disorders.

Figure 3: Prevalence rates* of the five psychiatric disorders in the FDRs and FDR+SDRs of the study participants

Figure 3A   Figure 3B

 Prevalence of any the five disorders are around 4 times higher in the first-degree relatives and 3 times higher in extended relatives (combined first- and second-degree relatives) of the study participants than the general population. Prevalence of BPAD in FDRs was nearly 17 times (schizophrenia and OCD -6 times, AD-3 times, SUD- 2 times) higher than that of general population.

*Transdiagnostic prevalence in general population is calculated by sum of the prevalence rates of all five disorders in general population.

Transdiagnostic- Overall prevalence of any of the five disorders, SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness; Indian Gen.Pop. - Indian general Population prevalence (based on National mental health survey, Gururaj et al., 2016 and Mathuranath et al., 2010).

Table S1: <u>Baseline characteristics (continuous variables) of participants across different diagnostic categories</u>[a]

		SUD (n=165) mean (SD)	BD (n=151) mean (SD)	AD (n=76) mean (SD)	OCD (n=117) mean (SD)	SCZ (n=150) mean (SD)	COMPLEX SMI (n=114) mean (SD)	OTHER DISORDERS (n=82) mean (SD)	UNAFFECTED RELATIVES (n=551) mean (SD)	TOTAL (n=1406) mean (SD)
Age	(in years)	43.07 (12.57)	39.79 (13.48)	67.66 (9.63)	36.01 (14.53)	40.91 (13.32)	40.5 (14.1)	42.99 (15.47)	42.17 (15.35)	42.66 (15.5)
Education	(in years)	7.69 (4.76)	8.87 (5.77)	7.93 (5.67)	12.44 (4.27)	8.69 (4.76)	10.52 (4.61)	10.01 (5.38)	10.52 (5.07)	9.81 (5.2)
Age at Onset	(in years)	27.32 (10.23)	23.69 (9.93)	64.8 (9.52)	22.21 (10.66)	27.19 (9.34)	25.36 (11.89)	-	-	29.33 (15.89)
Duration of Illness	(in years)	15.95 (12.04)	16.31 (11.91)	2.75 (1.82)	13.75 (11.46)	13.92 (11.58)	15.48 (10.93)	-	-	13.77 (11.79)
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Sex	Male	154 (93.33%)	67 (44.37%)	34 (44.74%)	65 (55.56%)	65 (43.33%)	90 (78.95%)	31 (37.8%)	294 (53.36%)	800 (56.9%)
	Female	11 (6.67%)	84 (55.63%)	42 (55.26%)	52 (44.44%)	85 (56.67%)	24 (21.05%)	51 (62.2%)	257 (46.64%)	606 (43.1%)
Habitat	Rural	54 (32.93%)	68 (46.26%)	39 (51.32%)	40 (34.48%)	79 (54.11%)	43 (38.39%)	31 (37.8%)	205 (37.61%)	559 (40.27%)
	Urban	110 (67.07%)	79 (53.74%)	37 (48.68%)	76 (65.52%)	67 (45.89%)	69 (61.61%)	51 (62.2%)	340 (62.39%)	829 (59.73%)
Marital Status	Divorced or separated	4 (2.44%)	4 (2.74%)	(0%)	3 (2.59%)	15 (10%)	2 (1.77%)	1 (1.23%)	9 (1.64%)	38 (2.72%)
	Living as couple	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	1 (0.18%)	1 (0.07%)
	Married	124 (75.61%)	87 (59.59%)	68 (89.47%)	62 (53.45%)	78 (52%)	60 (53.1%)	56 (69.14%)	405 (73.64%)	940 (67.34%)
	Unmarried	33 (20.12%)	49 (33.56%)	(0%)	50 (43.1%)	53 (35.33%)	50 (44.25%)	17 (20.99%)	118 (21.45%)	370 (26.5%)
	Widowed	3 (1.83%)	6 (4.11%)	8 (10.53%)	1 (0.86%)	4 (2.67%)	1 (0.88%)	7 (8.64%)	17 (3.09%)	47 (3.37%)
Occupation	Government employee	10 (6.1%)	5 (3.38%)	4 (5.26%)	8 (6.96%)	3 (2.01%)	3 (2.65%)	4 (4.88%)	41 (7.5%)	78 (5.6%)
	Homemaker	4 (2.44%)	47 (31.76%)	19 (25%)	33 (28.7%)	47 (31.54%)	13 (11.5%)	26 (31.71%)	113 (20.66%)	302 (21.66%)

Non-government employee	39 (23.78%)	28 (18.92%)	1 (1.32%)	19 (16.52%)	20 (13.42%)	19 (16.81%)	20 (24.39%)	134 (24.5%)	280 (20.09%)
Non-paid job	(0%)	(0%)	(0%)	(0%)	1 (0.67%)	(0%)	(0%)	1 (0.18%)	2 (0.14%)
Refused	(0%)	(0%)	(0%)	(0%)	1 (0.67%)	(0%)	(0%)	(0%)	1 (0.07%)
Retired	3 (1.83%)	1 (0.68%)	18 (23.68%)	2 (1.74%)	3 (2.01%)	4 (3.54%)	4 (4.88%)	28 (5.12%)	63 (4.52%)
Self-employed	94 (57.32%)	38 (25.68%)	9 (11.84%)	12 (10.43%)	21 (14.09%)	32 (28.32%)	18 (21.95%)	166 (30.35%)	390 (27.98%)
student	2 (1.22%)	12 (8.11%)	(0%)	26 (22.61%)	8 (5.37%)	6 (5.31%)	6 (7.32%)	50 (9.14%)	110 (7.89%)
Unemployed (able to work)	9 (5.49%)	14 (9.46%)	(0%)	9 (7.83%)	23 (15.44%)	18 (15.93%)	2 (2.44%)	11 (2.01%)	86 (6.17%)
Unemployed (unable to work)	3 (1.83%)	3 (2.03%)	25 (32.89%)	6 (5.22%)	22 (14.77%)	18 (15.93%)	2 (2.44%)	3 (0.55%)	82 (5.88%)

[a] The largest numbers of subjects available for each study group are presented. Proportion of missing data ranged from 0.71% to 1.28% for various sociodemographic factors.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; SCZ- Schizophrenia; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.

Table S2: Prevalence rates of the five psychiatric disorders in the FDRs as well as FDRs and SDRs of individuals from multiplex families across diagnostic categories

Diagnosis in Participants	P_{SUD}		P_{BD}		P_{AD}		P_{OCD}		$P_{Schizophrenia}$		$P_{Transdiagnosis}$	
	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives
SUD	25.91%	22.89%	0.56%	0.56%	3.15%	1.88%	1.56%	0.85%	0.65%	0.56%	32.33%	26.75%
BD	5.00%	4.20%	13.01%	13.01%	5.54%	3.42%	1.49%	0.92%	0.00%	0.10%	36.75%	21.64%
Schizophrenia	6.27%	4.62%	1.90%	1.92%	20.13%	9.35%	1.68%	0.73%	0.19%	0.08%	31.95%	16.68%
OCD	4.15%	4.54%	1.80%	1.63%	3.80%	2.17%	20.73%	10.24%	0.30%	0.26%	31.44%	18.99%
AD	4.80%	4.22%	1.00%	1.00%	1.68%	1.57%	0.61%	0.52%	11.41%	10.60%	19.66%	17.90%
Complex SMI	13.68%	10.49%	5.36%	5.89%	4.75%	3.29%	6.76%	3.41%	1.77%	1.51%	33.42%	24.06%
Other Psychiatric Disorder	10.29%	8.21%	5.95%	5.21%	9.13%	4.86%	4.78%	2.34%	1.00%	0.58%	35.77%	21.94%
Unaffected	9.14%	8.78%	5.26%	5.21%	8.21%	5.35%	4.89%	2.69%	3.10%	3.09%	33.35%	25.17%
Total	9.69%	8.57%	5.14%	5.09%	7.66%	4.64%	4.63%	2.59%	2.31%	1.83%	32.72%	22.76%

P-Prevalence; SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.

Figure S1: <u>100% stacked column of distribution of psychiatric symptoms count in participants across diagnostic categories as measured by DSM5 level-1 cross-cutting measure.</u>

Each stack represents the number of symptom domain screened positive in DSM5 cross cutting symptom measure. Less than 30% of study participants have no clinically significant symptoms. But nearly 50% have 2 or more domains of symptoms in the last 2 weeks displaying the intra-individual phenotypic diversity.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.